Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S et al. High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011; 29: 3214–3223.

    Article  CAS  Google Scholar 

  2. Borges VF, Elias AD . The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest. J Clin Oncol 2011; 29: 3205–3206.

    Article  Google Scholar 

  3. Elfenbein GJ . Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003; 349: 80–82.

    Article  Google Scholar 

  4. André T, Boni C, Mounedji-Boudiaf L . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–2351.

    Article  Google Scholar 

  5. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005; 366: 1935–1944.

    Article  CAS  Google Scholar 

  6. Marino P, Roché H, Moatti JP . PEGASE Group. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis. Am J Clin Oncol 2008; 31: 117–124.

    Article  CAS  Google Scholar 

  7. Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006; 17: 588–596.

    Article  CAS  Google Scholar 

  8. Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008; 19: 861–870.

    Article  CAS  Google Scholar 

  9. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA et al. Prognostic model for relapse after high dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002; 20: 707–718.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Martino.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castagna, L., Martino, M. Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?. Bone Marrow Transplant 48, 305 (2013). https://doi.org/10.1038/bmt.2012.126

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.126

Search

Quick links